Skip to content

Oruka Therapeutics, Inc. ORKA Investment Purchases

Investment Purchases at other companies

Eli Lilly logo
Eli LillyLLY
$297M+50.8%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$144M-42.6%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$276.27M+230%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$68.97M-67.8%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$62.15M+10.8%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$139.09M+138,993%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireMarketableSecurities.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s investment purchases.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s investment purchases?
Oruka Therapeutics, Inc. (ORKA) reported investment purchases of $90.83M in Q1 2026.
How has Oruka Therapeutics, Inc.'s investment purchases changed year-over-year?
Oruka Therapeutics, Inc.'s investment purchases increased by 105.1% year-over-year, from $44.29M to $90.83M.
What does investment purchases mean?
Cash spent purchasing investment securities across all categories.